Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:BCDA NASDAQ:BIVI NASDAQ:GRI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.74+1.8%$1.60$1.26▼$4.50$12.43M2.2920,186 shs45,589 shsBCDABioCardia$1.09+1.9%$1.18$1.00▼$2.91$11.71M0.56328,140 shs150,080 shsBIVIBioVie$1.38+5.3%$1.44$1.06▼$12.10$9.88M0.72108,238 shs59,018 shsGRIGRI Bio$2.15-4.9%$2.43$2.09▼$80.36$3.27M-1.2241,134 shs36,577 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+1.75%+1.69%+5.45%+14.47%-34.22%BCDABioCardia+1.87%0.00%-7.63%-4.39%-60.65%BIVIBioVie+5.34%-10.39%-5.48%+8.66%-87.45%GRIGRI Bio-4.87%-4.44%-11.89%-6.93%-94.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$1.74+1.8%$1.60$1.26▼$4.50$12.43M2.2920,186 shs45,589 shsBCDABioCardia$1.09+1.9%$1.18$1.00▼$2.91$11.71M0.56328,140 shs150,080 shsBIVIBioVie$1.38+5.3%$1.44$1.06▼$12.10$9.88M0.72108,238 shs59,018 shsGRIGRI Bio$2.15-4.9%$2.43$2.09▼$80.36$3.27M-1.2241,134 shs36,577 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+1.75%+1.69%+5.45%+14.47%-34.22%BCDABioCardia+1.87%0.00%-7.63%-4.39%-60.65%BIVIBioVie+5.34%-10.39%-5.48%+8.66%-87.45%GRIGRI Bio-4.87%-4.44%-11.89%-6.93%-94.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 1.00SellN/AN/ABCDABioCardia 2.00Hold$25.002,193.58% UpsideBIVIBioVie 1.00SellN/AN/AGRIGRI Bio 2.33Hold$1,008.0046,783.72% UpsideCurrent Analyst Ratings BreakdownLatest GRI, BIVI, AIMD, and BCDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026AIMDAinos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026GRIGRI Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026BCDABioCardia Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026BIVIBioVie Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$120K105.42N/AN/A$1.29 per share1.35BCDABioCardia$60K198.74N/AN/A$0.08 per share13.63BIVIBioVieN/AN/AN/AN/A$2.07 per shareN/AGRIGRI BioN/AN/AN/AN/A$4.16 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.77M-$2.89N/AN/AN/A-11,912.10%-144.01%-62.00%N/ABCDABioCardia-$8.23M-$1.29N/AN/AN/AN/A-28,372.40%-238.22%5/15/2026 (Estimated)BIVIBioVie-$17.54M-$3.25N/AN/AN/AN/A-101.15%-90.18%N/AGRIGRI Bio-$11.96M-$235.02N/AN/AN/AN/A-289.01%-171.12%5/21/2026 (Estimated)Latest GRI, BIVI, AIMD, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026GRIGRI Bio-$3.74N/AN/AN/AN/AN/A5/15/2026Q1 2026BCDABioCardia-$0.17N/AN/AN/AN/AN/A5/13/2026Q1 2026AIMDAinosN/A-$0.41N/A-$0.41N/AN/A5/13/2026Q1 2026GRIGRI Bio-$3.74-$1.61+$2.13-$1.61N/AN/A5/11/2026Q3 2026BIVIBioVie-$0.73-$0.70+$0.03-$0.70N/AN/A3/30/2026Q4 2025AIMDAinosN/A-$0.85N/A-$0.85N/AN/A3/24/2026Q4 2025BCDABioCardia-$0.20-$0.06+$0.14-$0.06$0.03 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ABIVIBioVieN/AN/AN/AN/AN/AGRIGRI Bio$1.9188.84%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos1.451.060.78BCDABioCardiaN/A1.121.12BIVIBioVieN/A9.967.25GRIGRI BioN/A3.253.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/ABCDABioCardia20.57%BIVIBioVie4.59%GRIGRI Bio33.95%Insider OwnershipCompanyInsider OwnershipAIMDAinos9.79%BCDABioCardia17.40%BIVIBioVie0.90%GRIGRI Bio8.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos407.27 million6.56 millionNot OptionableBCDABioCardia4010.94 million9.04 millionOptionableBIVIBioVie107.54 million7.47 millionNo DataGRIGRI Bio11.45 million1.32 millionNot OptionableGRI, BIVI, AIMD, and BCDA HeadlinesRecent News About These CompaniesGRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued ...May 14 at 2:53 PM | markets.businessinsider.comGRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating PipelineMay 14 at 8:35 AM | globenewswire.comGRI Bio (GRI) Expected to Announce Quarterly Earnings on ThursdayMay 14 at 2:25 AM | americanbankingnews.comGRI Bio (GRI) price target decreased by 75.16% to 163.20April 9, 2026 | msn.comGRI Springs on UAE PatentApril 9, 2026 | baystreet.caGRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory ConditionsApril 8, 2026 | globenewswire.comGRI Bio, Inc. Discusses Positive Phase 2a Data in Idiopathic Pulmonary Fibrosis During Virtual Investor SegmentFebruary 17, 2026 | quiverquant.comQGRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” SegmentFebruary 17, 2026 | globenewswire.comGRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull FinancialFebruary 5, 2026 | globenewswire.comGRI Bio, Inc.: GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent HighlightsFebruary 4, 2026 | finanznachrichten.deGRI Bio (GRI) price target increased by 2,700.00% to 656.88February 4, 2026 | msn.comGRI Bio, Inc. Reports Strong Cash Position and Positive Phase 2a Results for GRI-0621 in Pulmonary FibrosisFebruary 4, 2026 | quiverquant.comQGRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent HighlightsFebruary 4, 2026 | globenewswire.comGRI Bio Expands At-The-Market Equity Offering CapacityJanuary 30, 2026 | tipranks.comGRI Bio, Inc.: GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPFJanuary 29, 2026 | finanznachrichten.deGRI Bio reports positive study results for chronic lung disease, but stock slumps 20% — what happened?January 29, 2026 | msn.comGRI Bio stock soars after gene data shows IPF drug targets disease driversJanuary 28, 2026 | in.investing.comGRI Bio, Inc. Reports Positive Phase 2a Results for GRI-0621 as Disease-Modifying Therapy in Idiopathic Pulmonary FibrosisJanuary 28, 2026 | quiverquant.comQGRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPFJanuary 28, 2026 | globenewswire.comGRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound StructuresJanuary 26, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines1 Stock Is Powering the AI Boom and the Next Farm SupercycleBy Jeffrey Neal Johnson | April 22, 2026Chipotle Stock Just Hit Bottom—Is a Breakout Next?By Thomas Hughes | April 30, 2026The USMCA Review Is Coming: 3 Border-Sensitive Stocks to WatchBy Chris Markoch | May 8, 2026Astera Labs: The Tollbooth for AI's Traffic JamBy Jeffrey Neal Johnson | April 23, 20263 Agriculture Stocks to Buy as Food Inflation Stays Elevated in 2026By Chris Markoch | April 20, 2026GRI, BIVI, AIMD, and BCDA Company DescriptionsAinos NASDAQ:AIMD$1.74 +0.03 (+1.75%) Closing price 05/14/2026 03:58 PM EasternExtended Trading$1.80 +0.06 (+3.51%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.BioCardia NASDAQ:BCDA$1.09 +0.02 (+1.87%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.12 +0.03 (+2.75%) As of 05:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.BioVie NASDAQ:BIVI$1.38 +0.07 (+5.34%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.34 -0.03 (-2.54%) As of 05:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.GRI Bio NASDAQ:GRI$2.15 -0.11 (-4.87%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$2.20 +0.05 (+2.33%) As of 05:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
